CJC-1295, sermorelin and tesamorelin belong to the growth-hormone-releasing hormone (GHRH) research area, but their names do not describe interchangeable materials. A useful comparison begins with the molecular structure, especially whether a CJC-labelled material includes the albumin-binding modification used in the original CJC-1295 literature. 1 2 3
Compare the structures first
| Compound | Structural distinction | What to verify |
|---|---|---|
| Sermorelin | GHRH(1–29)-amide, the biologically active N-terminal fragment. 1 | Sequence, terminal amidation and salt form. |
| CJC-1295 in the original albumin-binding research | A modified GHRH analogue designed to form an albumin conjugate. 2 | The exact structure, including the albumin-binding group. |
| Tesamorelin | The 44-amino-acid GHRH sequence with an N-terminal hexenoyl modification. 3 | The full sequence and N-terminal modification. |
The important CJC-1295 naming trap
Moleano's published CJC report is labelled “no DAC”. That qualifier matters. The foundational CJC-1295 paper investigated GHRH–albumin bioconjugates, and the subsequent prolonged-action study described DAC-GRF. A report or listing marked “no DAC” should not inherit that compound's persistence claims merely because both names contain CJC-1295. Check the supplied sequence and modification against the material in the paper. 2 4
For a literature review, record the full chemical description beside every result. Keep evidence for the albumin-binding construct separate from evidence for a material lacking that modification. If the supplier documentation does not settle which structure is present, clarification is more useful than choosing a convenient half-life from a search result. This is a rule for interpreting the comparison, not a claim that a product name alone proves identity.
Sermorelin and tesamorelin ask different structural questions
Sermorelin's 29-residue amidated fragment and tesamorelin's modified 44-residue structure provide a clear example of why “GHRH analogue” is a family description. It is not a specification. The NLM record identifies sermorelin as GHRH(1–29)-amide; the FDA chemistry review describes the added hexenoyl group on tesamorelin's N-terminal tyrosine. Those details belong in any research-material comparison. 1 3
A shared research pathway does not, by itself, establish equal activity under a particular assay condition. A meaningful comparison needs the same endpoint and an appropriate experimental design. Treat a ranking such as “strongest” as incomplete unless it identifies what was measured, in which model, and for which exact molecules. The structural sources cited here do not establish a universal ranking between these three catalogue names.
Read the analytical evidence alongside the literature
Ask for the sample identifier, expected molecular mass, sequence specification, chromatographic method and quantitative content basis. Chromatographic purity and net peptide content answer different questions; a high main-peak percentage does not establish the milligram amount of the target material. Mass spectrometry provides another identity check, but interpreting it requires the expected structure and the limitations of the method. 5
Use the COA reading guide to organise those checks and the purity versus net-content guide to keep the measurements separate. For this comparison, the most useful first decision is whether the research question concerns a native fragment, a modified full-length analogue or an albumin-binding construct.
See the available lab reports and product specifications for CJC-1295, Sermorelin and Tesamorelin. Confirm the exact material before transferring a finding from a paper to a research plan.
Frequently asked questions
Can no-DAC CJC material use the persistence claims from DAC studies?
Not without evidence for that exact material. The original CJC-1295 research examined an albumin-binding construct; check the sequence and modification in the report and paper.
Is sermorelin the same structure as tesamorelin?
No. Sermorelin is GHRH(1–29)-amide. Tesamorelin has the 44-residue GHRH sequence with an N-terminal hexenoyl modification.
Sources
- NLM MeSH - Sermorelin, GHRH(1–29)-amide
- Jetté et al. - GHRH-albumin bioconjugates and CJC-1295, Endocrinology 2005
- FDA - Tesamorelin chemistry review, 2010
- Teichman et al. - CJC-1295 (DAC-GRF), JCEM 2006
- Bachem - Quality control of amino acids and peptides
Research use only. All products sold by Moleano Peptides are intended solely for laboratory research. They are not for human or veterinary use and are not drugs, supplements or medical devices. This guide is educational and is not medical advice.